Sexual function and depressive symptoms in men with hypoprolactinaemia secondary to overtreatment of prolactin excess: A pilot study.
Depresión
Depression
Dopaminergic agents
Función sexual
Fármacos dopaminérgicos
Hipofunción lactotrofa
Hombres
Lactotroph hypofunction
Men
Prolactin
Prolactina
Sexual function
Journal
Endocrinologia, diabetes y nutricion
ISSN: 2530-0180
Titre abrégé: Endocrinol Diabetes Nutr (Engl Ed)
Pays: Spain
ID NLM: 101717565
Informations de publication
Date de publication:
28 Jun 2021
28 Jun 2021
Historique:
received:
19
12
2020
revised:
17
03
2021
accepted:
28
03
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
aheadofprint
Résumé
Low prolactin levels have been found to impair libido and arousal, as well as to reduce wellbeing in young women. The aim of this study was to investigate whether drug-induced hypoprolactinaemia affects male sexual function and depressive symptoms. The study population consisted of three groups of young and middle-aged men. Two groups were treated with dopamine agonists because of previous hyperprolactinaemia but differed in current prolactin levels, which were <3ng/ml (n=12; group 1) or within the reference range (3-20ng/ml) (n=20; group 2). The control group (group 3) included 24 dopamine agonist-naïve normoprolactinaemic men. During the study, doses of dopaminergic agents in group 1 were reduced by 25-50% compared to doses before the start of the study. Circulating levels of prolactin, testosterone, free calculated testosterone, dehydroepiandrosterone-sulphate, oestradiol and gonadotropins were measured upon enrolment in the study and six months later. Moreover, at the beginning and the end of the study, all men enrolled completed questionnaires assessing sexual functioning (IIEF-15) and depressive symptoms (BDI-II). Group 1 differed from groups 2 and 3 in domain scores for sexual desire and erectile function, and in the overall BDI-II score. It was also characterised by lower levels of total testosterone and calculated free testosterone. Reduction of drug doses normalised sexual desire and erectile function, reduced BDI-II scores and increased prolactin as well as total and free calculated testosterone. Groups 2 and 3 did not differ from each other in sexual functioning, depressive symptoms or hormone levels. The results obtained indicate that men with dopamine agonist-induced hypoprolactinaemia are characterised by impaired sexual functioning and reduced wellbeing. These disturbances are a consequence of subnormal prolactin levels and do not seem to reflect adverse effects of dopamine agonists.
Sections du résumé
BACKGROUND
BACKGROUND
Low prolactin levels have been found to impair libido and arousal, as well as to reduce wellbeing in young women.
OBJECTIVE
OBJECTIVE
The aim of this study was to investigate whether drug-induced hypoprolactinaemia affects male sexual function and depressive symptoms.
METHODS
METHODS
The study population consisted of three groups of young and middle-aged men. Two groups were treated with dopamine agonists because of previous hyperprolactinaemia but differed in current prolactin levels, which were <3ng/ml (n=12; group 1) or within the reference range (3-20ng/ml) (n=20; group 2). The control group (group 3) included 24 dopamine agonist-naïve normoprolactinaemic men. During the study, doses of dopaminergic agents in group 1 were reduced by 25-50% compared to doses before the start of the study. Circulating levels of prolactin, testosterone, free calculated testosterone, dehydroepiandrosterone-sulphate, oestradiol and gonadotropins were measured upon enrolment in the study and six months later. Moreover, at the beginning and the end of the study, all men enrolled completed questionnaires assessing sexual functioning (IIEF-15) and depressive symptoms (BDI-II).
RESULTS
RESULTS
Group 1 differed from groups 2 and 3 in domain scores for sexual desire and erectile function, and in the overall BDI-II score. It was also characterised by lower levels of total testosterone and calculated free testosterone. Reduction of drug doses normalised sexual desire and erectile function, reduced BDI-II scores and increased prolactin as well as total and free calculated testosterone. Groups 2 and 3 did not differ from each other in sexual functioning, depressive symptoms or hormone levels.
CONCLUSIONS
CONCLUSIONS
The results obtained indicate that men with dopamine agonist-induced hypoprolactinaemia are characterised by impaired sexual functioning and reduced wellbeing. These disturbances are a consequence of subnormal prolactin levels and do not seem to reflect adverse effects of dopamine agonists.
Identifiants
pubmed: 34210634
pii: S2530-0164(21)00145-2
doi: 10.1016/j.endinu.2021.03.001
pii:
doi:
Types de publication
Journal Article
Langues
eng
spa
Informations de copyright
Copyright © 2021 SEEN y SED. Publicado por Elsevier España, S.L.U. All rights reserved.